Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone™ Rabbit Monoclonal Antibodies and their detection systems for pathology applications. These diagnostic immunohistochemistry (IHC) products are manufactured by the In Vitro Diagnostic (IVD) Division of the Company. This new line of products are developed in compliance with regulation for IHC antibodies and detection systems in the United States, these products are manufactured under FDA's Quality System Regulation (21 CFR, Part 820). Each product is either labeled "In Vitro Diagnostics (IVD)" or "Analyte Specific Reagents (ASR)" based on its intended application.
"By launching diagnostic IHC products into the rapidly growing pathology market, we have achieved another major milestone for Epitomics rabbit monoclonal antibody (RabMAb®) technology" said Dr. Guo-Liang Yu, President and CEO of Epitomics, Inc. "Precision detection of biomarkers in cancers is critical for cancer treatment. RabMAbs have been proven to be the "best in class" immunologic probes for detecting cancer and other disease targets in pathologic tissues. We have developed a broad portfolio of RabMAbs for pathologists to use to generate meaningful information to help diagnose and aid physicians to design better treatment strategies. We are proud that our technology will provide great benefits to the diagnosis and treatment of cancer".
COVID booster in lactating mothers can provide antibodies for infants